Navigation Links
Rosetta Genomics Announces Three New Diagnostic Tests to Enter Development
Date:6/18/2008

coverage and adequate payment from health insurers for the products and services comprising Rosetta's technology; competition from others using technology similar to Rosetta's and others developing products for similar uses; Rosetta's dependence on collaborators; and Rosetta's short operating history; as well as those risks more fully discussed in the "Risk Factors" section of Rosetta's Annual Report on Form 20-F for the year ended December 31, 2006 as filed with the Securities and Exchange Commission. In addition, any forward-looking statements represent Rosetta's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.

(1) American Cancer Society website, 2008

(2) Travis WD, Colby TV, Corrin B, et al.: Histological typing of lung and pleural tumours. 3rd ed. Berlin: Springer-Verlag, 1999.

Contact: Media

Rachel Spielman

T: +1-212-583-2714

E: media@rosettagenomics.com

Investors

Ron Kamienchick

T: +1-646-509-1893

E: investors@rosettagenomics.com


'/>"/>
SOURCE Rosetta Genomics Ltd
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007
2. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma
3. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
4. Rosetta Genomics to Webcast Presentation at Maxim Group Growth Conference
5. Rosetta Genomics to Host and Webcast its R&D Day on Friday, October 26, 2007
6. Rosetta Genomics Will Host and Webcast its R&D Day on Friday, October 26, 2007
7. Rosetta Genomics Announces Initiation of In Vivo Studies Following Successful Completion of First Milestone in MicroRNA-based Therapeutic Program for Liver Cancer
8. Rosetta Genomics Selects PCR as Platform for its microRNA-based Diagnostics to be Launched in 2008, Licensed Nanogens MGB Probe Technology
9. Rosetta Genomics and Columbia University Medical Center to Develop MicroRNA-based Diagnostics for Leukemia and Non Hodgkin Lymphoma
10. Rosetta Genomics Announces Initiation of Expansion of US Operations to Facilitate Expected Product Launches in 2008
11. Henry Ford Hospital and Rosetta Genomics to Develop MicroRNA-based Diagnostics for Brain Cancer

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)... Peregrine Pharmaceutical...ill release its financial results for the second q... 7:00 a.m. EST and will host a conference call and...on the same day. ,, Peregrine,s senior manageme...uarter ended October 31, 2009 and will review rece...
(Date:12/2/2009)...Newswire-FirstCall/ -- Martek Biosciences Corporat...ds to release the results of its fourth quarter an...imately 4:00 p.m. Eastern Time (ET). Following th...onference call to discuss these results with inves...ll live via webcast by visiting Martek,s web site ...
(Date:12/2/2009)...ewswire/ -- Reportlinker.com announces that a new ...ue: ,, Drug Discovery Technologies - A Global ... http://www.reportlinker.com/p0164246/Drug-Discov...s--Opportunities.html ,, Drug discovery has be...maceutical company,s business strategy. There are ...
(Date:12/2/2009)...ewswire-FirstCall/ - Oncolytics Biotech Inc. ("Onc...) announced today that in connection with its prev...ave exercised in full their over-allotment option ...it is comprised of one common share and 0.4 of a c...ice of US$3.00 per unit. Each whole common share p...
Breaking Biology Technology:Peregrine Pharmaceuticals to Report Second Quarter FY 2010 Financial Results 2Martek to Announce Fourth Quarter and Fiscal Year 2009 Results 2Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 2Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 3Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 4Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 5Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 6Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 7Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 8Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 9Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 2Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 3Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 4
...., Feb. 3 Genomic Health,Inc. (Nasdaq: GHDX ) t...ess for,the fourth quarter and year ended December...ter of 2008 increased to $31.2 million,compared wi...roduct revenue,from the Oncotype DX(R) breast canc...f 2008, an increase of 60 percent, compared with $...
...Newswire-FirstCall/ - Victhom Human Bionics Inc., ...obionix division has obtained CE Mark approval for... for a closed-loop system (CLS) used on peripheral...eded for the sale of the Neurostep(TM) in any of t...ostep(TM), a fully implantable investigational neu...
...hite Paper Reports More Than 75% of Biotech Firms ...ship in Next Three Years , , NEW YORK, Feb. 3 Mo...plore business partnerships and strategic alliance...ding to "Plumbing the Depths," a new white paper r... www.rkco.com ). Results were based on the finding...
Other Biology Technology:Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 2Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 3Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 4Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 5Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 6Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 7Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 8Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 9Victhom Human Bionics Receives CE Mark for the Neurostep(TM) System, the World's First Fully Implantable Closed-Loop Neuromodulation Therapy for Treatment of Foot Drop 2Victhom Human Bionics Receives CE Mark for the Neurostep(TM) System, the World's First Fully Implantable Closed-Loop Neuromodulation Therapy for Treatment of Foot Drop 3Volatile Economy / Fundraising Challenges Encourage Business Combinations Among Biotech Companies According to New Survey from CPA Firm Rothstein Kass 2Volatile Economy / Fundraising Challenges Encourage Business Combinations Among Biotech Companies According to New Survey from CPA Firm Rothstein Kass 3Volatile Economy / Fundraising Challenges Encourage Business Combinations Among Biotech Companies According to New Survey from CPA Firm Rothstein Kass 4
(Date:12/3/2009)...LADELPHIA Now in its 32nd year, the CTRC-AACR San...act the best in breast cancer science and world le...eradicating breast cancer. , This year, more th...ather at the Henry B. Gonzales Convention Center i...is a partnership between the American Association ...
(Date:12/3/2009)...est dwellers must be included in the design of the...oid a humanitarian crisis, according to a scientis...n Nature , Dr Simon Lewis argues that at least 50...penhagen, known as REDD (Reducing Emissions from D...orest dwellers directly, and their property rights...
(Date:12/2/2009)...HILADELPHIA Children exposed to secondhand cigare...g cancer in adulthood, even if they never smoked. ...r Epidemiology, Biomarkers & Prevention , a journa... as part of a special tobacco focus in the Decembe...mericans will be diagnosed with lung cancer; more ...
Breaking Biology News(10 mins):CTRC-AACR San Antonio Breast Cancer Symposium continues to expand 2Forest deal at Copenhagen must avoid creating 'carbon refugees' 2Secondhand smoke exposure in childhood increases lung cancer risk later in life 2Over 60 Firms Confirmed to Attend CBIs Third Annual Bio Pharmaceutical Collaboration and Transaction Accounting Conference in September 13715 1Over 60 Firms Confirmed to Attend CBIs Third Annual Bio Pharmaceutical Collaboration and Transaction Accounting Conference in September 13715 2Memorial Blood Centers in Urgent Need of Type O Negative and Type B Negative Blood Donors 55487 1Memorial Blood Centers in Urgent Need of Type O Negative and Type B Negative Blood Donors 55487 2ATS Medical Announces FDA Approval for a Landmark Clinical Investigation of the ATS 3f Aortic Bioprosthesis 4905 1ATS Medical Announces FDA Approval for a Landmark Clinical Investigation of the ATS 3f Aortic Bioprosthesis 4905 2ATS Medical Announces FDA Approval for a Landmark Clinical Investigation of the ATS 3f Aortic Bioprosthesis 4905 3
...nstitute have discovered that a protein known as F...rts of the body may have a function in the regulat...cate tissues that cannot survive the "inflammation...hat this discovery may ultimately help in the deve...h as macular degeneration and autoimmune diseases ...
... Department of Energy,s Pacific Northwest National...e machinery of life -- bringing us one step closer...he environment and protecting the country against ...ed "sequence alignment tool" that can divide the w...ragments so large data sets can run on many proces...
...ity genes by screening the genome of Caenorhabditi...ganism in genetics studies. The findings are repor...h of the 23 genes somehow normally acts to reduce ...eases lifespan. For example, the worm,s lifespan d...operly, and inhibition of another gene increases t...
Other Biology News:A protein in the eye may prevent immune response and protect eyes from disease 2Genomic sequences processed in minutes, rather than weeks 2
GR4 Auto Access 100V/50-60Hz from Thermo Scientific
...UF040A is a diluent that is designed for use with ...ies which are paired with a mouse monoclonal coati...d mouse proteins to prevent non-specific binding b...ll; This buffer may be used to stabilize newly c...
EZ-Tn5 Transposase from EPICENTRE Biotechnologies
...BL's bioassays for interferons are cytopathic effe...ral assays. Sample types include; tissue culture ...ormulations. In these assays, one unit is defined...iter to reduce the cytopathic effect of viral infe...
Biology Products: